Here, we studied the effect of chemerin/RARRES2 overexpression using the transplantable orthotopic syngeneic EMT6 breast carcinoma model, which has been shown to be responsive to immunomodulation in a variety of settings (29–31). The gene discussed is RARRES2; the disease is breast carcinoma.